QIAGEN N.V. · ISIN: NL0012169213 · EQS - adhoc news

QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase

Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase Venlo, the Netherlands, January 7, 2024 – QIAGEN N.V. announces a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. QIAGEN has decided to implement the maximum $300 million value of the man...

NYSE:QGEN Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News QIAGEN N.V.

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (14)
Short Selling (UK) (0)
07 January 2024 07:03PM
QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
NL0012169213
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase Venlo, the Netherlands, January 7, 2024 – QIAGEN N.V. announces a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repu...
QIAGEN N.V.
About the publication
26 July 2022 07:46PM
QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
NL0012169213
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN increases full-year 2022 outlook Venlo, The Netherlands, July 26, 2022 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it has increased the outlook for full-year 2022 in terms of net sales and adjusted diluted earnings per share (EPS). QIAGEN increa...
QIAGEN N.V.
About the publication
26 July 2022 07:46PM
QIAGEN increases full-year 2022 outlook
NL0012169213
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN increases full-year 2022 outlook Venlo, The Netherlands, July 26, 2022 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it has increased the outlook for full-year 2022 in terms of net sales and adjusted diluted earnings per share (EPS). QIAGEN increa...
QIAGEN N.V.
About the publication
26 April 2022 07:57PM
QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
NL0012169213
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN increases full-year 2022 outlook Venlo, The Netherlands, April 26, 2022 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it has increased the outlook for full-year 2022 in terms of net sales and adjusted diluted earnings per share (EPS). Net sales ar...
QIAGEN N.V.
About the publication
12 July 2021 05:13PM
QIAGEN N.V.: QIAGEN announces preliminary Q2 2021 results and updates 2021 outlook
NL0012169213
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN announces preliminary Q2 2021 results and updates 2021 outlook Venlo, the Netherlands, July 12, 2021 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces preliminary results for the second quarter of 2021 that exceeded the outlook for net sales and adjusted ea...
QIAGEN N.V.
About the publication
12 July 2021 05:12PM
QIAGEN N.V.: QIAGEN to conduct an additional up to USD 100 million share repurchase program
NL0012169213
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN to conduct an additional up to USD 100 million share repurchase program Venlo, The Netherlands, July 12, 2021 - QIAGEN N.V. announces that its Managing Board, upon authorization of the Supervisory Board, has today passed a resolution to exercise the authorization granted by t...
QIAGEN N.V.
About the publication
10 December 2020 07:49AM
QIAGEN N.V.: QIAGEN N.V. launches non-U.S. offering of net share settled convertible bonds and solicits offers from non-U.S. holders to sell any and all of the outstanding convertible notes due 2021
NL0012169213
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Ad-hoc announcement pursuant to A...
QIAGEN N.V.
About the publication
27 October 2020 05:44PM
QIAGEN N.V.: QIAGEN increases full-year 2020 outlook
NL0012169213
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN increases full-year 2020 outlook Venlo, the Netherlands, October 27, 2020 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it has increased the outlook for full-year 2020 net sales growth to about 20% at constant exchange rates (CER) (prior outlook of...
QIAGEN N.V.
About the publication
13 October 2020 02:42PM
QIAGEN N.V.: QIAGEN reports strong preliminary results for third quarter of 2020
NL0012169213
QIAGEN reports strong preliminary results for third quarter of 2020 Venlo, The Netherlands, October 13, 2020 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces preliminary sales and adjusted earnings per share (EPS) results for the third quarter of 2020. Net sales grew 26% at actual rates, and also rose 26% at constant exchange ...
QIAGEN N.V.
About the publication
21 August 2020 05:43PM
QIAGEN N.V.: Resignation of Chairman of the Supervisory Board
NL0012169213
Ad hoc Announcement according to Art. 17 Market Abuse Regulation Resignation of Chairman of the Supervisory Board Venlo, The Netherlands, August 21, 2020 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that Dr. Håkan Björklund, Chairman of the Supervisory Board, has resigned from office as Chairman of the Supervisory Board wi...
QIAGEN N.V.
About the publication
More QIAGEN N.V. related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 14 16th July 2020 Polar Asset Management Partners Inc. SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN